Thomas Raimondo, DO
Pulmonary Disease · Warwick, RINPI 1245236918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 27.1% of the total.
Across 385 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$1K
- Actelion Pharmaceuticals US, Inc.$409
- United Therapeutics Corporation$324
- Boehringer Ingelheim$314
- plus $2K from 21 others
What the payments were for
- Food & beverage$8,07298%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $2,225 |
| Sanofi | 54 | $1,487 |
| GSK | 73 | $1,309 |
| Actelion Pharmaceuticals US, Inc. | 13 | $409 |
| United Therapeutics Corporation | 15 | $324 |
| Boehringer Ingelheim | 14 | $314 |
| Amgen | 15 | $313 |
| Pharming Healthcare, Inc. | 9 | $201 |
| CSL Behring | 8 | $176 |
| Regeneron Healthcare Solutions, Inc. | 8 | $172 |
| Pfizer | 10 | $169 |
| Verona Pharma, Inc. | 8 | $155 |
| Hikma Pharmaceuticals USA | 8 | $134 |
| Mylan Specialty L.p. | 6 | $116 |
| Merck | 6 | $93 |
| Baxter Healthcare | 4 | $91 |
| Astellas Pharma US Inc | 2 | $83 |
| Philips North America LLC | 4 | $68 |
| Lilly USA, LLC | 4 | $66 |
| Inogen, Inc. | 3 | $61 |
| UCB, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Grifols USA, LLC | 2 | $35 |
| Bristol Myers Squibb | 2 | $35 |
| Insmed, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $18 |
How this compares
$8,218 in reported general payments places this provider in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 588 | $401,434 |
| Dupixent PenDupilumab | 25 | $131,082 |
| Breo ElliptaFluticasone/Vilanterol | 253 | $118,585 |
| Bosentan | 14 | $96,776 |
| Spiriva RespimatTiotropium Bromide | 93 | $59,715 |
| Dupixent SyringeDupilumab | 14 | $53,908 |
| Incruse ElliptaUmeclidinium Bromide | 96 | $40,269 |
| Sildenafil Citrate | 12 | $40,010 |
| Arnuity ElliptaFluticasone Furoate | 138 | $38,831 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $37,398 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $35,682 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $31,426 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 109 | $31,187 |
| EliquisApixaban | 46 | $27,382 |
| Spiriva HandihalerTiotropium Bromide | 25 | $27,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $1,309 | $630,5441,130 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat, Jardiance | $314 | $133,623233 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $409 | $96,77614 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $2,225 | $59,148131 claims |
| PfizerEliquis | $169 | $27,38246 claims |
| MerckDulera | $93 | $7,89225 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $35 | $4,93913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Warwick
- William CorraoWarwick$166K
- Anuradha RamaswamyWarwick$3K
- Elias JabbourWarwick$2K
- Stephen MatareseWarwick$2K
- Khalid AlhouraniWarwick$2K
- Ashish ThakkarWarwick$1K
- Neil LaboveWarwick$350
- Gerald WeinhouseWarwick$15
- Michael StanchinaEast Greenwich$219K
- Corey VentetuoloRiverside$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.